% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • dcaf7 dcaf7 Jan 28, 2013 8:21 PM Flag

    Belinostat in NSCLC

    is where real money could be made. Spectrum conducts phase 2 trial "Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)" which has a primary completion date as December 2012. Guess they already know the results.

5.62-0.37(-6.18%)Aug 24 4:00 PMEDT